“⚓[ 텔레 : ADSFIX01 ] 구글1페이지노출 블랙키워드 광고업체 블랙키워드 대행업체 구글 상단도배대행 구글 상단도배홍보 구글 상단도배광고⚓”的搜索结果，显示 191-200 项，共有 11988 项
The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a ...
... (1) Cohort 1 focuses on cancers displaying a high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression ...
Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...
Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...
In the study, 122 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2) ...
... 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy. ... The purpose of this study is to evaluate thymoma recurrence rates in patients who ...
... 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy. Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment ...
The purpose of this study is to evaluate molecular markers which might be a predictor of pancreatic cancer or precancer by analyzing the secretions (fluid) ...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has ...
Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will ...
妙佑医疗国际不为任何公司或产品背书。广告收入为我们的非营利使命提供支持。
浏览妙佑医疗国际出版社提供的畅销书以及书籍和简报的特别优惠。
您的捐赠可以抵税。请您慷慨解囊，和我们一起进行尖端研究和医护，共同推动医学的改变。